



Patent Docket P1134R2

E/17
1/17/00
2/25/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>Ashkenazi et al.</p> <p>Serial No.: 09/157,289</p> <p>Filed: September 18, 1998</p> <p>For: DcR3 Polypeptide, A TNFR Homolog</p>	<p>Examiner: C. Kaufman</p> <p>Art Unit: 1646</p> <hr/> <p>CERTIFICATE OF MAILING</p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on</p> <p>February 11, 2000</p> <p><i>Diane K. Marschang</i></p>
---	--

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATION
CONTAINING SEQUENCE DISCLOSURES**

Box Sequence

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

This paper is being filed in response to the Office communication mailed January 21, 2000. Entry of the following amendment is requested.

IN THE SPECIFICATION:

Please enter into the specification the attached substitute paper copy of the Sequence Listing which includes 10 pages and provides sequences identified as SEQ ID NOS: 1-16.

REMARKS

On January 21, 2000, the Patent Office mailed an office action setting forth a Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures. As the Examiner has noted, Applicants have filed responses to three previous Notices to Comply. Applicants have done so in a good faith effort to correct defects in the Sequence Listing. Given the impending inextensible deadline for correcting these